Reviewed clinical summary · Source-linked · Educational use only

Can a Culturally Tailored Program Improve Diabetes Care for Chinese Americans?

Clinical Bottom Line

A pilot RCT finds a culturally tailored WeChat-delivered programme improves self-efficacy and reduces diabetes distress in Chinese Americans with type 2 diabetes. PICO summary and commentary.

Summary: In a pilot trial among Chinese American adults with type 2 diabetes, a culturally and linguistically tailored WeChat-delivered programme with community health worker support improved diabetes self-efficacy and dietary adherence and reduced diabetes distress, though it did not measure glycaemic outcomes.

PICO Summary

ElementDetail
Population60 Chinese American adults aged 18–70 with type 2 diabetes and baseline HbA1c ≥7%, mostly limited English proficiency (pilot RCT).
InterventionCARE programme: 12 weeks of tailored self-care videos via WeChat plus biweekly community health worker support calls (n=30).
ComparisonWaitlist control receiving usual care (n=30).
OutcomeImproved self-efficacy at 3 months (difference 8.47; 95% CI 2.44–14.5; P=.02), sustained healthy-diet adherence at 3 and 6 months (P=.02), and reduced diabetes distress at 6 months (difference -0.43; 95% CI -0.71 to -0.15; P=.009). No glycaemic endpoints in this analysis.
RCT JMIR Mhealth Uhealth · 2025

Culturally tailored WeChat diabetes programme (CARE)

Pilot RCT · Chinese Americans with T2D · 6 months

Trial design
Chinese American adults, T2D Enrolled & assessed RANDOMISED 1:1 CARE programme WeChat + CHW support n = 30 Control Waitlist, usual care n = 30 Self-efficacy, diabetes distress (between-group difference)
Between-group effect (95% CI)
0 (no difference) -2 16 Self-efficacy (diff)+8.47 ✓Diabetes distress (diff)-0.43 ✓ between-group mean difference (null = 0) · ✓ = significant
Self-efficacy diff
+8.47
95% CI 2.44 to 14.5
Distress diff
-0.43
95% CI -0.71 to -0.15
Diet adherence
Improved
P=.02 at 3 & 6 mo
Glycaemic outcome
Not measured
No HbA1c endpoint
⬡ Bottom Line

A culturally tailored WeChat programme with community health worker support improved self-efficacy and dietary adherence and lowered diabetes distress, but glycaemic outcomes were not assessed in this small pilot.

Expert Commentary

Reaching patients that standard diabetes education simply misses is a problem I care about, and delivering tailored content through WeChat with trusted community health workers is a smart, culturally intelligent way to do it for a markedly understudied group. The improvements in self-efficacy, dietary adherence, and diabetes distress are believable and worthwhile, and they fit the wider evidence that culturally tailored programmes reliably move psychosocial and behavioural measures. I keep my enthusiasm honest about two things. First, this is a pilot of 60 people with a waitlist control that received no attention, so some benefit is the effect of being engaged at all rather than the content. Second, and crucially, this analysis reports self-reported self-efficacy, distress, and diet, not HbA1c, and the familiar pattern in this field is that such programmes improve engagement more consistently than they improve glucose. Can I use this with my patients? Yes, in principle: partner with community health workers and signpost in-language resources for these communities. But I would frame it as an engagement-enhancing adjunct, not a glycaemic treatment, and await a larger trial with HbA1c outcomes.

References

Liu J, Cao J, Shi Y, et al. A culturally and linguistically tailored intervention to improve diabetes-related outcomes in Chinese Americans with type 2 diabetes: pilot randomized controlled trial. JMIR Mhealth Uhealth. 2025;13:e78036. doi:10.2196/78036

Educational use: Hormone Insight is intended for healthcare professionals and learners. Interpret each summary alongside the primary source, local guidance, and patient-specific clinical judgement.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.